FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. It is studied as a senolytic agent that selectively induces apoptosis in senescent cells while sparing normal cells.
Who's worth your money for FOXO4-DRI
Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.
Top Merit pick
Highest Merit Score (99) of 6 scored sellers
$135 · 10mg · 99.9% purity
Best value
Lowest $/mg among scored sellers
$119 · 10mg · 100.0% purity
Most tested
3 independent COAs on file
$275 · 10mg · 99.8% purity
Average price
$19.65/mg
Sellers
36
45-day trend
-0.4%
32 of 36 sellers have a current price· 14 stale hidden· 12 unverified hidden
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · 23h ago
$13.50/mg -31.3% vs avg$135
10mg
- 🇺🇸 BioLongevity Labs96
✓ verified at source · 23h ago
$27.50/mg +39.9% vs avg$275
10mg
- 🇺🇸 Ion Peptide95
✓ verified at source · 23h ago
$11.90/mg -39.4% vs avg$119
10mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · 23h ago
$20.00/mg +1.8% vs avg$200
10mg
no purityBuy code Orbitrex10 · 10% off - 🇺🇸 Peptide Tech94
✓ verified at source · 23h ago
$15.00/mg -23.7% vs avg$150
10mg
- 🇺🇸 Verified Peptides86
via Disclosed Labs · 23h ago
$22.00/mg +11.9% vs avg$220
10mg
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
Watch FOXO4-DRI
Get one email when the market actually moves — no newsletter, no noise.
About FOXO4-DRI
CAS
2460055-10-9
Molecular formula
C228H388N86O64
Sequence
LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRPPPRRRQRRKKRG
Typical dose range
1 mg subcutaneous, repeated on alternating days (e.g. days 1, 3, 5) per cycle; original mouse research used 5 mg/kg × 3 doses
Half-life
~2–6 hours (estimated preclinical; no human PK data available)
COAs for FOXO4-DRI
20 third-party tests across 9 vendors. Each card links to the full report.
For
FOXO4-DRI
by Verified Peptides· batch FOX062602108
For
FOX04-DRI
by Ion Peptide· batch FOX10-04022026
For
FOXO4-DRI
by BioLongevity Labs· batch 261153
For
FOXO4-DRI
by Peptidology· batch 1671
For
FOX04-DRI
by Real Peptides
For
FOXO4-DRI
by Skye Peptides· batch FOX26-15-001
For
FOXO4-DRI
by Ascension Peptides· batch 55-01260229
For
FOXO4-DRI
by Ascension Peptides· batch 55-01260229
For
FOXO4-DRI
by Glacier Aminos· batch FOX10GA01
For
FOXO4-DRI
by Kimera Chems· batch KC-FX4-GRY1
For
FOXO4-DRI
by Verified Peptides· batch 03-25-0110A
For
FOX-04
by Simple Peptide· batch cmp9xk4yj00329trx7cgpf22y
For
FOXO4-DRI
by Peptide Tech· batch F4D-5195
For
FOXO4-DRI
by BioLongevity Labs· batch cmojb7f8i01b6kirxq6ddannn
For
FOXO4-DRI
by Kimera Chems· batch Black Cap
For
FOXO4-DRI
by BioLongevity Labs· batch cmojb7qk401dukirxq2vhxw8n
Purity not on file
For
FOX04-DRI
by Real Peptides
Purity not on file
For
FOXO4-DRI
by Skye Peptides· batch FOX26-15-001
Purity not on file
For
FOXO4-DRI
by Peptide Tech· batch F4D-5195
Purity not on file
For
FOXO4-DRI
by Verified Peptides· batch 03-25-0110A
12 citations indexed for FOXO4-DRI
review · 2026
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline
Cellular senescence, driven by the interaction between FOXO4 and p53, is increasingly recognized as a crucial mechanism in brain aging and the development of neurodegenerative disorders.
Study · 2026
Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence
Temozolomide (TMZ) is still the first-line drug for glioblastoma (GBM) treatment though tumor cell resistance remains a major challenge.
review · 2026
The right time, the right cell: the potential for precision senotherapy in pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a fatal vasculopathy driven by proinflammatory signaling that leads to pulmonary vascular remodeling and ultimately, right ventricular failure. Existing therapies fail to eliminate dysfunctional cells or reverse pathologic remodeling.
animal · 2025
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
Objectives Endothelial cell dysfunction during aging is a key driver of vascular aging and related diseases; however, effective strategies to selectively eliminate senescent endothelial cells and restore vascular function remain lacking.
Study · 2025
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
A central process contributing to the phenotype of aging is cellular senescence. We recently identified the FOXO4 - p53 axis as pivotal in maintaining the viability of senescent cells, and that senescent cells can be targeted selectively with the senolytic peptide FOXO4-DRI.
Study · 2025
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
Keloids are pathological scars exhibiting tumour-like aggressiveness and high recurrence rate.